Effects of nilotinib on regulatory T cells: the dose matters by Fei, Fei et al.
RESEARCH Open Access
Effects of nilotinib on regulatory T cells:
the dose matters
Fei Fei
1†, Yingzhe Yu
1†, Anita Schmitt
1,4, Markus T Rojewski
2, Baoan Chen
3, Jochen Greiner
1, Marlies Götz
1,
Donald Bunjes
1, Michael Schmitt
1,4*
Abstract
Background: Nilotinib is a tyrosine kinase inhibitor with high target specificity. Here, we characterized the effects
of nilotinib for the first time on CD4
+CD25
+ regulatory T cells (Tregs) which regulate anti-tumor/leukemia immune
responses.
Design and Methods: Carboxyfluorescein diacetate succinimidyl ester (CFSE) and 5-bromo-2-deoxy -uridine (BrdU)
were used to assess the proliferation and cell cycle distribution of Tregs. The expression of the transcription factor
forkhead box P3 (FoxP3) and the glucocorticoid-induced tumor necrosis factor receptor (GITR) were measured by
flow cytometry. Western blotting analysis was used to detect the effects of nilotinib on the signal transduction
cascade of T-cell receptor (TCR) in Tregs.
Results: Nilotinib inhibited the proliferation and suppressive capacity of Tregs in a dose-dependent manner.
However, the production of cytokines secreted by Tregs and CD4
+CD25
- T cells was only inhibited at high
concentrations of nilotinib exceeding the mean therapeutic serum concentrations of the drug in patients. Only
high doses of nilotinib arrested both Tregs and CD4
+CD25
- T cells in the G0/G1 phase and down-regulated the
expression of FoxP3 and GITR. In western blotting analysis, nilotinib did not show significant inhibitory effects on
TCR signaling events in Tregs and CD4
+CD25
- T cells.
Conclusions: These findings indicate that nilotinib does not hamper the function of Tregs at clinical relevant
doses, while long-term administration of nilotinib still needs to be investigated.
Introduction
Nilotinib (AMN107, Tasigna; Novartis Pharma, Basel,
Switzerland) is a new, orally active, selective inhibitor of
the ABL/BCR-ABL, CSF-1R, DDR, KIT, and PDGFR tyr-
osine kinases, that is more potent against chronic mye-
loid leukemia (CML) cells in vitro than is imatinib. Like
imatinib, nilotinib acts through competitive inhibition at
the ATP-binding site of BCR-ABL, leading to the inhibi-
tion of tyrosine phosphorylation of proteins that are
involved in the intracellular signal transduction
mediated BCR-ABL. Nilotinib has a higher binding affi-
nity and selectivity for the ABL kinase than does imati-
nib, which translates into 20- to 50-fold greater
inhibitory activity than imatinib in imatinib-sensitive
CML cells and 3- to 7-times the activity in imatinib-
resistant cell lines with mutant ABL kinases [1-5].
Results from a phase I dose escalation study performed
in patients with imatinib-resistant CML and Philadel-
phia (Ph) chromosome-positive acute lymphoblastic leu-
kemia (ALL) indicated that nilotinib produced
significant hematologic and cytogenetic responses in all
phases of CML [2]. Furthermore, 400 mg nilotinib was
administered orally twice daily, proved to be very active
and safe in phase II study of patients with chronic phase
CML and accelerated-phase CML post-imatinib resis-
tance and intolerance [6,7]. Now, clinical trials with
nilotinib are ongoing in patients with imatinib-resistant
or imatinib-intolerant accelerated-phase CML and Ph-
positive ALL [7,8].
Naturally arising CD4
+CD25
+ regulatory T cells
(Tregs) have the potential to suppress aberrant immune
responses and to regulate peripheral T-cell homeostasis
[9]. Tregs play a crucial role in both the induction and
maintenance of tolerance. This active immune
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immune responses to self-antigens, thereby preventing
autoimmune diseases, but also the control of responses
to non-self molecules in adaptive immunity. Numerous
experimental and clinical studies indicate that manipu-
lating the balance between regulatory and effector T
cells is an effective strategy to control immune respon-
siveness after transplantation. Therefore a better under-
standing of regulatory T cells biology is essential for
exploiting this strategy to clinical therapy [10].
There is evidence that imatinib and dasatinib have
inhibitory effects on immune reconstitution and T cell
proliferation and function [11-15]. Furthermore, niloti-
nib was shown to have an inhibitory effect on CD8
+ T
cells in vitro [16], however little is known about its
effects on Tregs [17]. Therefore, we wondered to what
extent and by which mechanisms nilotinib affects the
immune system, particularly for Tregs. In this study, we
examined the effects of nilotinib on both Tregs and
CD4
+CD25
- T cells. We indicate that nilotinib similarly
inhibits proliferation and function of Tregs as well as
CD4
+CD25
- T cells only at high concentrations greater
than 10 μM nilotinib which exceeds the therapeutic
range achieved with current standard dosing schedules.
Design and Methods
Nilotinib, imatinib and dasatinib
Nilotinib and imatinib were provided by Novartis Phar-
maceuticals, Basel, Switzerland. Dasatinib was purchased
from Bristol-Myers Squibb, New York, NY, USA and
stored in aliquots at -20°C as 10 mM stock solution in
DMSO.
Cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll-Biocoll Separation Solution (Biochrom,
Berlin, Germany) as described previously [18]. CD4
+CD25
+ T cells and CD4
+CD25
- T cells were selected
from the total PBMCs using CD4
+CD25
+ regulatory T
cell isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany), according to the manufacturer’s instruction.
This procedure led to the complete positive selection of
CD4
+CD25
+ T cells (purity ≥ 90%), and negative deple-
tion of CD4
+CD25
- T cells, as measured by flow cyto-
metry (FACSan, Becton Dickinson, Franklin Lake, NJ,
USA). Cells were cultured in RPMI 1640 (Biochrom
AG, Berlin, Germany) supplemented with 10% human
AB serum (Germany Red Cross Blood Center, Ulm,
Germany), 2 mM L-glutamine and 100 units/ml penicil-
lin-streptomycin (Invitrogen Gibco, Grand Island, USA).
CFSE-based cell proliferation
Isolated CD4
+CD25
+ T cells (1 × 10
6/ml) and CD4
+CD25
- T cells (1 × 10
6/ml) were labeled with 0.5 μM
vital dye carboxyfluorescein diacetate succinimidyl ester
(CFSE, Invitrogen Gibco, Grand Island, USA) just before
stimulation. Labeled CD4
+CD25
+ T cells (1 × 10
5/well)
or CD4
+CD25
- T cells (1 × 10
5/well) were stimulated
with anti-CD3 (OKT3; eBioscience, San Diego, CA,
USA) and 2 μg/ml soluble anti-CD28 (CD28.2, BD Phar-
mingen™, Heidelberg, Germany). 300 units/ml IL-2 was
used to expand CD4
+CD25
+ T cells. After 4 days of sti-
mulation, cell division was monitored by levels of CFSE
dilution. Unstimulated T cells served as negative control
in all experiments.
Suppression assay
CD4+CD25
+ T cells were incubated for 4 days with
CFSE
+-labeled CD4+CD25
- T cells, with each popula-
tion 5 × 10
4 cells in the presence of anti-CD3 and anti-
CD28. In some experiments, CD4
+CD25
+ T cells were
first incubated with nilotinib overnight, then the cells
were washed for three times and co-cultured with CFSE
+-labeled CD4
+CD25
- T cells as a ratio of 1:1 as men-
tioned above.
Apoptosis assay
CD4
+CD25
+ T cells and CD4
+CD25
- T cells were trea-
ted with nilotinib for 48 h. Cells were harvested and
stained with Annexin V* fluorescein isothiocyanate
(FITC) and propidium iodide (PI) (Annexin V*FITC
apoptosis detection kit I; BD Pharmingen™, Heidelberg,
Germany). Apoptotic cells were defined by flow cytome-
try as Annexin V positive and PI-negative cells.
Cell cycle analysis
An indirect 5-bromo-2-deoxyuridine (BrdU)-FITC flow
kit (BD Pharmingen™, Heidelberg, Germany) was used
to determine the cycle kinetics of CD4
+CD25
+ Tc e l l s
and CD4
+CD25
- T cells, and to measure the incorpora-
tion of BrdU into the DNA of proliferating cells. CD4
+CD25
+ T cells or CD4
+CD25
- T cells were treated with
different concentrations of nilotinib as indicated for 4
days. Cells were harvested and measured according to
the manufacturer’s instruction.
Cytokine analysis
CD4
+CD25
+ T cells and CD4
+CD25
- T cells were stimu-
lated with anti-CD3, anti-CD28 and IL-2 in the presence
or absence of 25 μM nilotinib. After 4 days incubation,
supernatants were collected and analyzed for cytokines
according to the instruction of Proteome Profiler Array
(R&D Systems, Minneapolis, MN, USA).
Flow cytometry
Cells were phenotyped by 4-o r5 -c o l o rA b sa n dm e a -
sured by flow cytometry as described previously [18].
The following conjugated Abs were used: CD4*
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Cyanine 7 (PE-Cy7), CD25* phycoerythrin-Cyanine 5
(PE-Cy5), CD25* Allophycocyanin (APC) (BD Pharmin-
gen™, Heidelberg, Germany), transcription factor fork-
head box P3 (FoxP3)*phycoerythrin (PE) (PCH 101;
eBioscience, San Diego, CA), and glucocorticoid-induced
tumor necrosis factor receptor (GITR)*PE (R&D Sys-
tems, Minneapolis, MN, USA),
Western blotting
CD4
+CD25
+ T cells, CD4
+CD25
- T cells or Jurkat T
cells (1 × 10
6 cells/well) were treated with different con-
centrations of imatinib, nilotinib or dasatinib for 1 hour
and stimulated with anti-CD3/CD28 for 15 minutes.
Western blotting analysis was performed as previously
described [18] by using the following antibodies: phos-
pho-Lck, Lck, phospho-ZAP-70, ZAP-70, phospho-p44/
42 MAP kinase, p44/42 MAP kinase, phospho-Akt, Akt,
src, phospho-src family (Tyr416), non-phospho-src
(Tyr416), phospho-src (Tyr527), non-phospho-src
(Tyr527), phospho-NF-B p65 (Ser536)(93H1) and NF-
B p65 from Cell Signaling Technology, USA and anti-
Actin C-11 (Santa Cruz Biotechnology, Heidelberg,
Germany) to confirm equal protein loading.
Statistical analysis
Statistical analysis was performed with SPSS software.
Data were presented as mean ± standard deviation (SD).
Statistical significance of differences between groups was
evaluated using one-way-ANOVA (post hoc Scheffe
test). The value of P < .05 was considered to be statisti-
cally significant.
Results
In phase I clinical studies, at the steady-state, mean
serum levels of nilotinib were: 1.0 μM at 400 mg once
daily, 1.7 μM at 400 mg twice daily, and 2.3 μMa t6 0 0
mg twice daily; at 400 mg twice daily, the dose selected
for phase II studies, steady state mean serum peak levels
of drug were 3.6 μM [2]. Based upon this, to include the
clinically relevant dose range of nilotinib, all assays
described in this manuscript were performed at concen-
trations between 1 and 25 μM.
Nilotinib inhibits the proliferation of CD4
+CD25
+ T cells
and CD4
+CD25
- T cells in a dose-dependent manner
Human CD4
+CD25
+ T cells could be expanded by anti-
C D 3 ,a n t i - C D 2 8a n dh i g hd o s e so fI L - 2( F i g u r e1 Aa n d
1C), in accordance with previous findings [19,20]. Addi-
tion of nilotinib inhibited the proliferation of both CD4
+CD25
+ T cells (Figure 1A and 1C) and CD4
+CD25
-T
cells (Figure 1B and 1D) in a dose-dependent manner as
shown in Figure 1. The effect was significant at concen-
trations of nilotinib greater than 10 μMa n d2 5μMf o r
CD4
+CD25
+ T cells and CD4
+CD25
- T cells respec-
tively. However the concentrations exceeded the mean
serum levels achieved in patients to whom nilotinib was
administered.
Nilotinib has no inhibitory effect on the suppressive
capacity of CD4
+CD25
+ T cells
Our dose-dependent proliferation assays indicated that
nilotinib at a concentration between 1-25 μMi ss u b o p t i -
mal for the inhibition of the CD4
+CD25
+ T cells and
CD4
+CD25
- T cells. Therefore, the use of these concen-
trations of nilotinib would allow us to assess an addi-
tional inhibition of CD4
+CD25
- Tc e l l sb ya d d i n gC D 4
+CD25
+ T cells. We observed that adding nilotinib to the
co-cultures led to an additional inhibition of CD4
+CD25
-
T cells proliferation (Figure 2A) which might be the rea-
son that nilotinib had a inhibitory effect on CD4
+CD25
-
T cells. Nilotinib at a concentration up to 25 μM did not
hamper the suppressive capacity of CD4
+CD25
+ T cell.
To further investigate the effect of nilotinib on the
suppressive capacity of CD4
+CD25
+ T cells, CD4
+CD25
+ T cells were first incubated with or without different
concentrations of nilotinib overnight in the presence of
IL-2. Then, cells were washed three times to remove
nilotinib and co-cultured together with CFSE
+-labeled
CD4
+CD25
- T cells at a 1:1 ratio. After four days incu-
bation, the proliferation of CD4
+CD25
- T cells was mea-
sured by flow cytometry. To clarify whether CD4
+CD25
+ T cells viability could be reduced by overnight incuba-
tion, we first measured the viability of CD4
+CD25
+ T
cells and CD4
+CD25
- T cells after overnight incubation
by staining cells with Annexin V*FITC and 7-AAD.
Nilotinib did not reduce the viability of CD4
+CD25
+ T
cells and CD4
+CD25
- T cells after pre-incubation over-
night (data not shown). As shown in Figure 2B, nilotinib
inhibited the suppressive capacity of CD4
+CD25
+ T cells
at concentrations higher than 5 μM.
Nilotinib does not induce apoptosis of CD4
+CD25
+ T cells
or CD4
+CD25
- T cells
To assess whether nilotinib might induce apoptosis or
cell death in CD4
+CD25
+ T cells and CD4
+CD25
- T
cells. We incubated CD4
+CD25
+ T cells or CD4
+CD25
-
T cells with different concentrations of nilotinib as indi-
cated for 4 days and measured apoptosis and cell death
by Annexin V*FITC and PI staining. The percentage of
Annexin V*FITC-positive and PI-negative events of CD4
+CD25
+ T cells, which corresponds to apoptotic cells,
remained between 27.75 ± 14.05% to 42.05 ± 6.09%
compared with 44.53 ± 8.60% of untreated cells (P >
.05) (Figure 3). The percentage of apoptotic CD4
+CD25
-
T cells remained between 16.80 ± 4.70% to 22.15 ±
7.41% compared with 23.18 ± 8.20% of untreated cells.
According to apoptosis assay, CD4
+CD25
+ T cells are
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+CD25
+ T cells and CD4
+CD25
- T cells in a dose-dependent manner.C D 4
+CD25
+ T
cells or CD4+CD25
- T cells were labeled with CFSE and cultured with different concentrations of nilotinib as indicated. After 4 days incubation,
cells were harvested and stained with CD25 and FoxP3. Cell division was assessed by the dilution of CFSE. Panels A and B show the combined
results from four independent experiments with similar results. Displayed are mean values ± SD. Panels C and D display the results of a
representative experiment.
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+CD25
- T
cells in agreement with the characteristics described pre-
viously for Tregs [21].
Nilotinib arrests CD4
+CD25
+ T cells and CD4
+CD25
- T cells
accumulating in the G0/G1 phase at high concentrations
S i n c em a n yc y t o t o x i cd r u g sa r ee f f e c t i v et h r o u g hi n d u -
cing cell death, but also by causing an arrest in specific
phases of cell cycle, we next examined whether nilotinib
had an effect on cell cycle distribution. We stimulated
CD4
+CD25
+ T cells or CD4
+CD25
- T cells with anti-
CD3, anti-CD28 and IL-2 and measured cell cycle distri-
bution by BrdU staining. Anti-CD3 and anti-CD28, in
combination with IL-2, stimulated DNA synthesis in
both CD4
+CD25
+ T cells and CD4
+CD25
- T cells and
progressed cells into S phase, this effect was significantly
inhibited by nilotinib at concentrations > 10 μM (data
not shown), while nilotinib showed little significant inhi-
bitory effect on cell cycle distribution at concentrations
within the therapeutic dose range of the drug.
Nilotinib shows inhibitory effects on cytokine secretion of
CD4
+CD25
+ T cells and CD4
+CD25
- T cells
Cytokine production and release is a key process by
which activated T cells participate in immune responses;
Figure 2 Nilotinib does not hamper immunosuppressive
capacity of CD4
+CD25
+ T cells at clinical relevant doses. Panel
A: Purified CD4
+CD25
+ T cells or CD4
+CD25
- T cells (Teff) were
labeled with CFSE. CFSE
+-labeled CD4
+CD25
- T cells were stimulated
with anti-CD3 and anti-CD28 in the presence or absence of
nilotinib. The proliferation of CD4
+CD25
- T cells was measured by
the division of CFSE. Combined results from three independent
experiments were shown. Panel B: CD4
+CD25
+ T cells were first
incubated with different concentrations of nilotinib overnight in the
presence of IL-2. After washing cells for three times, CD4
+CD25
+ T
cells were co-cultured with CFSE
+-labeled CD4
+CD25
- T cells as a
ratio of 1:1. Cell division was assessed by levels of CFSE dilution.
Figure 3 Nilotinib does not induce apoptosis on CD4
+CD25
+ T
cells and CD4
+CD25
-T cells. CD4
+CD25
+ T cells (Panel A) and CD4
+CD25
-T cells (Panel B) were stimulated with anti-CD3, anti-CD28
and IL-2 with different concentrations of nilotinib as indicated for 48
h. Cells were then harvested and stained with Annexin V* FITC and
PI. Apoptotic cells were defined by flow cytometry as Annexin V
positive and PI negative cells.
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munity, GVHD and transplant rejection) cytokines are
involved in the pathophysiologic sequelae [22-24]. CD4
+CD25
+ T cells and CD4
+CD25
- T cells were stimulated
and treated with or without 25 μM nilotinib. After 4
days of incubation, supernatants were collected for cyto-
kine analysis (Figure 4). Nilotinib inhibited multiple
cytokines production including pro-inflammatory cyto-
kines (TNF-a,I F N - g,a n dI L - 1 r a) and chemotactic fac-
tors (MIP-1b,M C P - 1 ,R A N T E S ,I P - 1 0 ,e t c )b yC D 4
+CD25
- T cells at a high concentration of 25 μM. CD4
+CD25
+ T cells only secreted few cytokines compared
with CD4
+CD25
- T cells (Figure 4C and 4D). T-cell
receptor (TCR)-mediated activation Tregs were proved
to have very low in vitro proliferative capacity and they
do not produce cytokines compared with other T cells
[25]. However, nilotinib inhibits the cytokines produc-
tion by CD4
+CD25
+ T cells significantly at a concentra-
tion of 25 μM.
Nilotinib down-regulates the expression of CD4
+CD25
+ T
cell-specific molecules in a dose-dependent manner
To investigate the inhibitory effect of nilotinib on the
phenotype of CD4
+CD25
high T cells, CD4
+CD25
+ T cells
Figure 4 Nilotinib inhibits the cytokine production by CD4
+CD25
+ Tc e l l sa n dC D 4
+CD25
- T cells.P a n e lA :C D 4
+CD25
+ Tc e l l sw e r e
stimulated with anti-CD3, anti-CD28 and IL-2 in the presence or absence of 25 μM nilotinib. After 4 days incubation, supernatants were
collected for cytokine analysis. The high intensity spots in the three corners are positive controls, the lower right contains the negative controls.
Panel B: Graphs of the relative density (subtracted the average background signals) are shown for selected cytokines. Array images are shown in
panel A and profiles created by quantifying the background-subtracted mean spot pixel densities are identified as shown in Panel B by using
image analysis software. Panel C + D: The cytokine production of CD4
+CD25
- T cells treated with nilotinib was analyzed by above methods.
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days. After stimulation, the expression of FoxP3 and
GITR were up-regulated compared with unstimulated
cells. However, nilotinib only at a concentration of 25
μM could down-regulate the expression of FoxP3 (P =
. 0 4 7 )a n dG I T R( P=. 0 0 4 )s i g n i f i c a n t l y( F i g u r e5 )w h i c h
was associated with the data in proliferation assay.
Nilotinib does not show signaling events on TCR in CD4
+CD25
+ T cells and CD4
+CD25
- T cells
CD4
+CD25
+ T cells and CD4
+CD25
- T cells were
incubated with or without different concentrations of
nilotinib for one hour. After incubation, cells were sti-
mulated with anti-CD3 and anti-CD28 for 15 minutes.
Nilotinib did not significantly decrease the levels of p-
Lck and p-ZAP even at a high concentration of 25 μM
as shown in Figure 6A.
Furthermore, we compared the effects of nilotinib,
imatinib and dasatinib on TCR, Src and NF-Bd e p e n -
dent signal cascades in Jurkat T cells. Figure 6B clearly
shows that exposure of cells to low nanomolar concen-
trations of dasatinib attenuated the phosphorylation
levels of Lck, ZAP-70, ERK 1/2, AKT, Src Tyr416, Src
Tyr527 and NF-B P65 in a dose-dependent manner.
Imatinib only showed significant effects at a dose of 25
μM which is 100-fold higher concentrations than dasati-
nib. In contrast, nilotinib showed no significant inhibi-
tion of TCR, Src and NF-B signal events, even at a
high concentration of 25 μM.
Discussion
The novel, selective Abl inhibitor nilotinib was designed
to interact with the ATP-binding site of BCR-ABL with
a higher affinity than imatinib. Besides being signifi-
cantly more potent when compared with imatinib, nilo-
tinib also maintains activity against most of the BCR-
ABL point mutants that confer to imatinib resistance. In
phase I/II clinical trials administration of nilotinib
resulted in cytogenetic and hematologic responses in
imatinib-refractory CML patients [2].
Now nilotinib represents an additional therapeutic
option for patients with progressive CML [26].
Naturally occurring Tregs represent between 5% and
10% of the CD4
+ T cell subset in the peripheral blood
of healthy volunteers [27,28]. Studies of T-cell mediated
immunoregulation provide crucial insights into the
immune system’st a s ko fb a l a n c i n gi m m u n o l o g i cs e l f -
tolerance, while preserving tumor and anti-microbial
immunity. Tregs have emerged as key cellular compo-
nents that mediate this process [9]. In the stem cell
transplantation setting, Tregs have proved to be effective
in suppressing lethal graft versus host disease (GVHD).
Importantly, this suppression does not abrogate the ben-
eficial graft versus tumor (GVT) effect in most murine
models. Moreover, in preliminary studies, donor Tregs
promote engraftment and enhance immune reconstitu-
tion [9]. Recently, patients with CML are treated with
nilotinib when the therapy with imatinib failed or
caused serious side effects [2]. The same applies to the
situation of CML patients after allogeneic stem cell
transplantation. Moreover, patients with a history of
nilotinib administration before transplantation are likely
to be treated again by the drug in the case of a relapse
of the disease after allogeneic stem cell transplantation.
Therefore, the effect of nilotinib on Treg function needs
to be monitored [9,29].
Figure 5 High concentrations of nilotinib down-regulate the
expression of FoxP3 and GITR by CD4
+CD25
+ T cells. Purified
CD4
+CD25
+ T cells were unstimulated or stimulated with anti-CD3,
anti-CD28 and IL-2 in the presence or absence of nilotinib as indicated.
Then cells were stained with FoxP3*PE or GITR*PE according to the
manufacturer’s instruction for fixation, permeabilization, and staining,
after cells were stained for surface expression of CD4 and CD25.
Nilotinib significantly decreased the intracellular expression of FoxP3
and GITR on CD4
+CD25
+ T cells in a dose-dependent manner at
concentrations of 25 μM. Data are representative of four independent
experiments with similar results. Displayed are mean values ± SD.
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nib as an immunomodulatory agent, we set our studies
on three important parts of T cell responses: TCR sig-
naling and expression of activation markers, cytokine
production, and proliferation [13]. In our study, we
observed that therapeutic doses of nilotinib did not
hamper the proliferation and function, of either CD4
+CD25
+ T cells or CD4
+CD25
- T cells. Nilotinib only
showed significant inhibitory effect on CD4
+CD25
+ T
cells or CD4
+CD25
- T cells at a concentration higher
than 10 μM. However, Chen et al showed that nilotinib
inhibits phytohemagglutinin (PHA)-induced proliferation
of CD8
+ Tc e l l sin vitro at therapeutically relevant con-
centrations (0.5-4 μM) [16]. Similar results were also
shown by Blake et al. [30]. We think the difference
between us might be the reason we use anti-CD3, anti-
CD28 and IL-2 to stimulate CD4
+CD25
+ T cells and
CD4
+CD25
- T cells which is stronger than PHA that
could partly abrogate the inhibitory effect of nilotinib on
cells. However, the correlates between nilotinib and T
cells in vivo are still unknown and it is still not clear
which assays are more appropriate in gauging the sup-
pressive effect of nilotinib. Furthermore, our results pre-
sent that nilotinib did not affect the suppressive capacity
of Tregs at therapeutically relevant concentrations, only
at a concentration of 5 μM. Tregs and nilotinib act in
s y n e r g yt or e d u c eC D 4
+CD25
- T cells proliferation
when co-cultured at the same time. We propose that
the reason is that the direct inhibitory effect of nilotinib
on CD4
+CD25
- T cells might be stronger than the indir-
ectly inhibitory effect on the proliferation of CD4
+CD25
-
T cells by Tregs.
The recent identification of the FoxP3, as a more spe-
cific marker of Tregs better defines the regulatory subset
of CD4
+ T cells from activated effector T cells [9]. Based
on consistent findings in mice and humans, FoxP3 is
considered the “master regulator” of Tregs [9]. GITR is
highly and constitutively expressed on the surface of
mouse and human Tregs. Stimulation of GITR in vitro
or in vivo or the removal of T cells expressing high
levels of GITR leads to autoimmunity in normal mice
[31,32]. In our study, we observed that high doses of
nilotinib down-regulated the expression of FoxP3 and
GITR in Tregs in a dose-dependent manner, which was
accordance to the function of Tregs.
In the next step, we investigated the signaling events in
CD4+CD25+ T cells and CD4+CD25- T cells after treat-
ment with nilotinib. Consistent with previous data, niloti-
nib did not impair the phosphorylation levels of Lck and
ZAP70 in cells even at a high concentration of 25 μM.
Furthermore, we compared the inhibitory effects of imati-
nib, nilotinib and dasatinib on signal events against Jurkat
T cells. An interesting phenomenon is that imatinib-resis-
tant CML patients who develop resistance against nilotinib
Figure 6 Nilotinib does not inhibit the signaling events on TCR
in CD4
+CD25
+ T cells and CD4
+CD25
- T cells. Panel A: Purified
CD4
+CD25
+ T cells and CD4
+CD25
- T cells were incubated with
nilotinib for 1 hour. Then cells were not stimulated or stimulated
with anti-CD3/CD28 for 15 minutes. Whole cell lysates were
analyzed by western blotting for the phosphorylation levels of Lck
and Zap70. (1. non stimulated CD4
+CD25
+ T cells; 2. non stimulated
CD4
+CD25
- T cells; 3. stimulated CD4
+CD25
+ T cells; 4. stimulated
CD4
+CD25
- T cells; 5. stimulated CD4
+CD25
+ T cells plus nilotinib; 6.
stimulated CD4
+CD25
- T cells plus nilotinib; 7. stimulated CD4
+CD25
-
T cells plus nilotinib; 8. stimulated CD4
+CD25
- T cells plus nilotinib;
the respective concentration of nilotinib is indicated in the figure.)
Panel B: Comparison of imatinib, nilotinib and dasatinib on the
effects of TCR, Src and NF-B signaling molecules in the Jurkat cell
line. Compared with imatinib and dasatinib, nilotinib did not show
obvious inhibitory effects in Jurkat T cells, while dasatinib showed
the highest inhibitory potency among the three drugs. Data are
representative of three experiments with similar results.
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Page 8 of 10may still show a response to dasatinib, and patients with
resistance against dasatinib may still respond to nilotinib
[33]. Another remarkable aspect is that, in contrast to
nilotinib, dasatinib exhibits a number of clinically relevant
side effects including cytopenia and pleural effusions when
applied at approved doses [34]. All these observations
point to major differences of the three tyrosine kinase
inhibitors regarding their mechanism of action and target
profiles in pathological as well as normal cells [33]. We
demonstrated that among the three drugs, dasatinib
showed the highest potency on TCR, Src and NF-Bs i g -
naling events, while nilotinib did not show inhibitory
effects on this signaling transduction cascade, which is in
accordance with the molecular mechanisms of the three
drugs. Previous biochemical studies have already revealed
pronounced differences between the three tyrosine kinase
inhibitors with regard to their selectivity. Nilotinib, like
imatinib, inhibits BCR-ABL, c-ABL, c-KIT, and PDGFR,
although with greater potency and selectivity for BCR-
ABL [5]. The selectivity of nilotinib against BCR-ABL
(relative to other targets, such as Src-family or c-Kit
kinases) may account for the high level of efficacy unac-
companied by higher rates of severe myelosuppression [6].
Dasatinib, on the other hand, has been developed as a
dual-specificity Abl- and Src-family kinase inhibitor [35].
Moreover, several pathways of the immune system could
be severely affected by continuous high doses of dasatinib,
harboring significant risks for immunosuppression of
patients treated over a long period of time [33]. Recently,
our group shows that imatinib inhibits the proliferation
and function of Tregs and CD8
+ T cells as a concentration
range of 1-5 μM, while the range for dasatinib is 5-10 nM
[18,36,37]. Larmonier et al reported that imatinib inhibits
the suppressive function and FoxP3 expression on Tregs
as low as 1 μM. In vivo study indicated that imaitnib
decreases Treg frequency and impairs their immunosup-
pressive function for mice treated with imatinib but imati-
nib does not impair the production of IL-10 and TGF-b in
vitro [38]. Dasatinib proves to be much more potent than
imatinib and nilotinib on Tregs and CD8
+ T cells. Chow
et al. reported that although nilotinib exhibits only a
minor apoptosis-inducing effect in the T-cell lines, it
exerts a considerable, dose-dependent cytotoxicity in the
B-cell lines. The activity of nilotinib is not restricted to
Bcr-Abl, c-kit, or PDGFR-positive cells, but also extends
to lymphatic cell lines of B-cell origin at a concentration
of 5 μM [39]. Furthermore, Hipp et al. indicated that the
multitargeted tyrosine serine/threonine kinase inhibitor
sunitinib could significantly decrease the number of Tregs
in the peripheral blood of mice treated with subtoxic
doses of the drug, but does not show an impaired CD8
+ T
cell response [40]. As all these compounds have already
entered clinical practice, it would be useful to further
define the appropriate clinical angle, because it would
allow a rational approach to balance effector T cells and
Tregs especially for patients after allogeneic stem cell
transplantation.
In conclusion, our results show that the tyrosine
kinase inhibitor nilotinib can inhibit both proliferation
and function of Tregs and CD4
+CD25
- T cells only at
high concentrations, which exceeds therapeutically rele-
vant concentrations of the drug. Since nilotinib has less
inhibitory effects on Tregs than imatinib and dasatinib,
nilotinib might constitute a good choice for patients in
transplantation settings.
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